New hope for young cancer survivors: drug targets Treatment-Linked leukemia
NCT ID NCT05656248
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study tests an investigational drug called CPX-351 in 25 children and young adults (ages 1 to 21) who have developed a secondary blood cancer after previous cancer treatment. The goal is to see if the drug can put the cancer into remission so they can receive a stem cell transplant. The study focuses on safety and how well the drug works in this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.